Trichothiodystrophy Due to Ercc2 Variants: Uncommon Contributor to Progressive Hypomyelinating Leukodystrophy Publisher Pubmed



Tavasoli AR^{1, 2} ; Kaki A^{3, 4} ; Ganji M⁵ ; Kahani SM⁶ ; Radmehr F⁷ ; Mohammadi P^{2, 6} ; Heidari M² ; Ashrafi MR² ; Lewis KS¹ Show Affiliations
Source: Molecular Genetics and Genomic Medicine Published:2025

Abstract

Background: Trichothiodystrophy (TTD) is caused by homozygous or compound heterozygous variants in genes associated with DNA repair. The ERCC2 gene encoded a protein, XPD, that is a subunit of the general transcription factor TFIIH and important in both DNA repair and transcription. Disease-causing variants in ERCC2 can partially inactivate these activities, giving rise to symptoms seen in TTD, Cockayne syndrome (CS) and xeroderma pigmentosa (XP). Although generalized cerebral white matter abnormalities is reported in TTD, myelination disorders specifically linked to ERCC2 gene variants are exceptionally uncommon. Here, we introduce a thorough investigation of a patient exhibiting classic TTD symptoms alongside progressive cerebral hypomyelination with ERCC2 variants. Methods: In a non-consanguineous family, we conducted Autism/ID gene Panel on a 5-year-old affected child who presented with microcephaly, failure to thrive, developmental delay, and progressive hypomyelination on three serial brain imaging over 5-years follow-up. Our investigation aimed to elucidate the genetic underpinnings of the observed phenotype. We also conducted a comprehensive review of the genetic profiles of all documented ERCC2-related patients exhibiting myelination disorders. Results: Autism/ID gene Panel identified a compound heterozygous variant in ERCC2 gene causing TTD. Clinical and paraclinical findings enabled differentiation of TTD from Cockayne syndrome and XP. Segregation analysis revealed that, the variation in the paternal allele was a splice junction loss (c.2190 + 1delG), and the other alteration in the maternal allele was a pathogenic variant (c.1479 + 2dupT). It has been noted that these variants were reported in previous studies in homozygous or compound heterozygous form in patients with TTD, but none of them exhibited hypomyelinating leukodystrophy. Conclusion: The identification of hypomyelination in TTD due to ERCC2 sheds a light on the molecular diagnosis and contributing to the limited literature on ERCC2 variants and associated hypomyelinating leukodystrophy in patients with TTD. © 2025 The Author(s). Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.